Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

1.

Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.

Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T.

Mol Ther Nucleic Acids. 2015 Feb 3;4:e225. doi: 10.1038/mtna.2014.76.

2.

Scrub Typhus: Audit of an Outbreak.

Krishna MR, Vasuki B, Nagaraju K.

Indian J Pediatr. 2015 Jan 14. [Epub ahead of print]

PMID:
25586311
3.

VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis.

Dillingham BC, Knoblach SM, Many GM, Harmon BT, Mullen AM, Heier CR, Bello L, McCall JM, Hoffman EP, Connor EM, Nagaraju K, Reeves EK, Damsker JM.

Cell Mol Neurobiol. 2015 Apr;35(3):377-87. doi: 10.1007/s10571-014-0133-y. Epub 2014 Nov 13.

PMID:
25392236
4.

Non-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficits.

Heier CR, Guerron AD, Korotcov A, Lin S, Gordish-Dressman H, Fricke S, Sze RW, Hoffman EP, Wang P, Nagaraju K.

PLoS One. 2014 Nov 12;9(11):e112477. doi: 10.1371/journal.pone.0112477. eCollection 2014.

5.

Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.

Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, Hill DA, Partridge TA, Giri M, Freishtat RJ, Nazarian J, Xuan J, Wang Y, Hoffman EP.

J Cell Biol. 2014 Oct 13;207(1):139-58. doi: 10.1083/jcb.201402079.

PMID:
25313409
6.

Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases.

Tatem KS, Quinn JL, Phadke A, Yu Q, Gordish-Dressman H, Nagaraju K.

J Vis Exp. 2014 Sep 29;(91):51785. doi: 10.3791/51785.

PMID:
25286313
7.

Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Hathout Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H, Gordish-Dressman H, Cirak S, Bello L, Nagaraju K, Partridge T, Hoffman EP, Takeda S, Mah JK, Henricson E, McDonald C.

Hum Mol Genet. 2014 Dec 15;23(24):6458-69. doi: 10.1093/hmg/ddu366. Epub 2014 Jul 15.

PMID:
25027324
8.

Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion.

Defour A, Van der Meulen JH, Bhat R, Bigot A, Bashir R, Nagaraju K, Jaiswal JK.

Cell Death Dis. 2014 Jun 26;5:e1306. doi: 10.1038/cddis.2014.272.

9.

Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Kornegay JN, Spurney CF, Nghiem PP, Brinkmeyer-Langford CL, Hoffman EP, Nagaraju K.

ILAR J. 2014;55(1):119-49. doi: 10.1093/ilar/ilu011. Review.

10.

Mitotic asynchrony induces transforming growth factor-β1 secretion from airway epithelium.

Alcala SE, Benton AS, Watson AM, Kureshi S, Reeves EM, Damsker J, Wang Z, Nagaraju K, Anderson J, Williams AM, Lee AJ, Hayes K, Rose MC, Hoffman EP, Freishtat RJ.

Am J Respir Cell Mol Biol. 2014 Sep;51(3):363-9. doi: 10.1165/rcmb.2013-0396OC.

PMID:
24669775
11.

Synthesis, docking and evaluation of antioxidant and antimicrobial activities of novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazol-6-yl)selenopheno[2,3-d]pyrimidines.

Kotaiah Y, Nagaraju K, Harikrishna N, Venkata Rao C, Yamini L, Vijjulatha M.

Eur J Med Chem. 2014 Mar 21;75:195-202. doi: 10.1016/j.ejmech.2014.01.006. Epub 2014 Jan 22.

PMID:
24531232
12.

Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.

Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, Miller BK, Gordish-Dressman H, Ongini E, Miglietta D, Nagaraju K.

Hum Mol Genet. 2014 Jun 15;23(12):3239-49. doi: 10.1093/hmg/ddu033. Epub 2014 Jan 23.

PMID:
24463621
13.

The protein phosphatase 2A B56γ regulatory subunit is required for heart development.

Varadkar P, Despres D, Kraman M, Lozier J, Phadke A, Nagaraju K, Mccright B.

Dev Dyn. 2014 Jun;243(6):778-90. doi: 10.1002/dvdy.24111. Epub 2014 Feb 18.

PMID:
24425002
14.

Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle.

Henriques-Pons A, Yu Q, Rayavarapu S, Cohen TV, Ampong B, Cha HJ, Jahnke V, Van der Meulen J, Wang D, Jiang W, Kandimalla ER, Agrawal S, Spurney CF, Nagaraju K.

Hum Mol Genet. 2014 May 15;23(10):2604-17. doi: 10.1093/hmg/ddt656. Epub 2013 Dec 23.

PMID:
24368419
15.

Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice.

Quinn JL, Huynh T, Uaesoontrachoon K, Tatem K, Phadke A, Van der Meulen JH, Yu Q, Nagaraju K.

PLoS Curr. 2013 Nov 8;5. pii: ecurrents.md.e246cf493a7edb1669f42fb735936b46. doi: 10.1371/currents.md.e246cf493a7edb1669f42fb735936b46.

16.

Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target.

Rayavarapu S, Coley W, Van der Meulen JH, Cakir E, Tappeta K, Kinder TB, Dillingham BC, Brown KJ, Hathout Y, Nagaraju K.

Arthritis Rheum. 2013 Dec;65(12):3248-58. doi: 10.1002/art.38180.

17.

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.

Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, McCall JM, Hoffman EP, Reeves EK, Nagaraju K.

EMBO Mol Med. 2013 Oct;5(10):1569-85. doi: 10.1002/emmm.201302621. Epub 2013 Sep 9.

18.

The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands.

Uaesoontrachoon K, Cha HJ, Ampong B, Sali A, Vandermeulen J, Wei B, Creeden B, Huynh T, Quinn J, Tatem K, Rayavarapu S, Hoffman EP, Nagaraju K.

J Pathol. 2013 Oct;231(2):199-209. doi: 10.1002/path.4207.

19.

Cowden syndrome- Clinico-radiological illustration of a rare case.

Patil PB, Sreenivasan V, Goel S, Nagaraju K, Vashishth S, Gupta S, Garg K.

Contemp Clin Dent. 2013 Jan;4(1):119-23. doi: 10.4103/0976-237X.111634.

20.

The proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx mice.

Sali A, Many GM, Gordish-Dressman H, van der Meulen JH, Phadke A, Spurney CF, Cnaan A, Hoffman EP, Nagaraju K.

PLoS One. 2013 Jul 2;8(7):e66617. doi: 10.1371/journal.pone.0066617. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk